Your search history is turned on.
Date: April 1, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - BRPO_Q1 2024 CFO cert FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Gadi Levin, Chief Financial Officer of Briapro Therapeutics Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Briapro Therapeutics Corp. (the issue...
Microsoft Word - BRPO_Q1 2024 CEO cert FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Dr. William Williams, Chief Executive Officer of Briapro Therapeutics Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Briapro Therapeutics Corp. (...
Submission Proof - Z:\2024 OPERATIONS\EDGAR\02 FEBRUARY\BRIACELL THERAPEUTICS CORP\02-26-2024\Form 8-K_April 1, 2024\Draft\Prod BRIAPRO THERAPEUTICS CORP. MANAGEMENTS DISCUSSION AND ANALYSIS For the three and six months ended January 31, 2024 (Expressed in U.S. Dollars) The following Managements Discussion and Analysis (MD&A) for BRIAPRO THERAPEUTICS CORP. (...
Submission Proof - Z:\2024 OPERATIONS\EDGAR\02 FEBRUARY\BRIACELL THERAPEUTICS CORP\02-26-2024\Form 8-K_April 1, 2024\Draft\Prod BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTH PERIOD ENDED JANUARY 31, 2024 (Unaudited) (Expressed in United States Dollars) NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED...
Date: December 14, 2023 Jurisdictions: Alberta, British Columbia, Ontario
Microsoft Word - BRPO_Q1 2024 CFO cert FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Gadi Levin, Chief Financial Officer of Briapro Therapeutics Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Briapro Therapeutics Corp. (the is...
Microsoft Word - BRPO_Q1 2024 CEO cert FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Dr. William Williams, Chief Executive Officer of Briapro Therapeutics Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Briapro Therapeutics Corp...
Submission Proof - Z:\2023 OPERATIONS\EDGAR\11 November\BRIACELL THERAPEUTICS CORP\11-21-2023\Form 8-K_December 14, 2023\Draft\ BRIAPRO THERAPEUTICS CORP. MANAGEMENTS DISCUSSION AND ANALYSIS For the three months ended October 31, 2023 (Expressed in U.S. Dollars) The following Managements Discussion and Analysis (MD&A) for BRIAPRO THERAPEUTICS CORP. (BriaPro...
Submission Proof - Z:\2023 OPERATIONS\EDGAR\11 November\BRIACELL THERAPEUTICS CORP\11-21-2023\Form 8-K_December 14, 2023\Draft\ BRIAPRO THERAPEUTIC CORP. CONDESED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTH PERIOD ENDED OCTOBER 31, 2023 (Unaudited) (Expressed in United States Dollars) F-1 BriaPro Therapeutics Corp. Unaudited Condensed Interim Sta...
Date: October 25, 2023 Jurisdictions: Alberta, British Columbia, Ontario
_ FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Dr. William Williams, Chief Executive Officer of Briapro Therapeutics Corp., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial report and annual MD&A including for greater certainty, all documents and informati...
file:///Z:/2023%20OPERATIONS/2023%20EDGAR/10%20October/BriaCell BRIAPRO THERAPEUTICS CORP. MANAGEMENTS DISCUSSION AND ANALYSIS For the Year Ended July 31, 2023 (Expressed in U.S. Dollars) The following Managements Discussion and Analysis (MD&A) for BRIAPRO THERAPEUTICS CORP. (BriaPro or the Company) is prepared as of October 25, 2023 and relates to the ...